[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605363":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":186,"collaborators":188,"id":192,"slug":193,"hasResults":194,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":194,"sex":200,"minAge":201,"maxAge":202,"enrollmentInfo":203,"targetDuration":32,"studyType":206,"phases":207,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":42,"whyStopped":32,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":226},{"fullName":5,"class":6},"AAVantgarde Bio Srl","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","AAVB-039 dose level 1 (low dose)",[13],"Biological: AAVB-039",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","AAVB-039 dose level 2 (mid dose)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3","AAVB-039 dose level 3 (high dose)",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Cohorts 4-5","AAVB-039 dose level 1, 2 or 3",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"BIOLOGICAL","AAVB-039","Single subretinal administration",[9,15,19,23],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"AAVantgarde Clinical Operations Lead","CONTACT","+448000465680","clinicaltrials@aavantgarde.com",[40,61,80,96,113,126,141,157,175],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Associated Retina Consultants","RECRUITING","Phoenix","Arizona","85020","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-112.07404,33.44838,{"lat":52,"lon":51},[55,58],{"name":56,"role":36,"phone":32,"phoneExt":32,"email":57},"Study Team","hello@doctrials.com",{"name":59,"role":60,"phone":32,"phoneExt":32,"email":32},"Dr. Benjamin Bakall","PRINCIPAL_INVESTIGATOR",{"facility":62,"status":42,"city":63,"state":64,"zip":65,"country":46,"countryCode":47,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Retina Vitreous Associates Medical Group","Los Angeles","California","90211",{"type":49,"coordinates":67},[68,69],-118.24368,34.05223,{"lat":69,"lon":68},[72,75,78],{"name":73,"role":36,"phone":32,"phoneExt":32,"email":74},"Kristina Passoian, Trials Director","Kpassoian@laretina.com",{"name":76,"role":36,"phone":32,"phoneExt":32,"email":77},"Study Referrals","Studyreferrals@laretina.com",{"name":79,"role":60,"phone":32,"phoneExt":32,"email":32},"Dr. David Liao",{"facility":81,"status":42,"city":82,"state":83,"zip":84,"country":46,"countryCode":47,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"University of Florida Health Science Center","Jacksonville","Florida","32209",{"type":49,"coordinates":86},[87,88],-81.65565,30.33218,{"lat":88,"lon":87},[91,94],{"name":92,"role":36,"phone":32,"phoneExt":32,"email":93},"G. Shabbir Hamdani","Shabbir.hamdani@ufhealth.org",{"name":95,"role":60,"phone":32,"phoneExt":32,"email":32},"Dr. Sandeep Grover",{"facility":97,"status":42,"city":98,"state":99,"zip":100,"country":46,"countryCode":47,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Mayo Clinic","Rochester","Minnesota","55905",{"type":49,"coordinates":102},[103,104],-92.4699,44.02163,{"lat":104,"lon":103},[107,111],{"name":108,"role":36,"phone":109,"phoneExt":32,"email":110},"Suzy Wernimont","507-538-8119","Wernimont.Suzanne@mayo.edu",{"name":112,"role":60,"phone":32,"phoneExt":32,"email":32},"Dr. Brittni Scruggs",{"facility":114,"status":42,"city":115,"state":116,"zip":117,"country":46,"countryCode":47,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Retina Consultants of Texas","Bellaire","Texas","77401",{"type":49,"coordinates":119},[120,121],-95.45883,29.70579,{"lat":121,"lon":120},[124],{"name":125,"role":60,"phone":32,"phoneExt":32,"email":32},"Dr. Kenneth Fan",{"facility":127,"status":42,"city":128,"state":116,"zip":129,"country":46,"countryCode":47,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Retina Foundation of the Southwest","Dallas","75231",{"type":49,"coordinates":131},[132,133],-96.80667,32.78306,{"lat":133,"lon":132},[136,139],{"name":137,"role":36,"phone":32,"phoneExt":32,"email":138},"Senior Clinical Research Coordinator","jclark@retinafoundation.org",{"name":140,"role":60,"phone":32,"phoneExt":32,"email":32},"Dr. Karl Csaky",{"facility":142,"status":42,"city":143,"state":144,"zip":145,"country":46,"countryCode":47,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"University of Utah","Salt Lake City","Utah","84112",{"type":49,"coordinates":147},[148,149],-111.89105,40.76078,{"lat":149,"lon":148},[152,155],{"name":153,"role":36,"phone":32,"phoneExt":32,"email":154},"Kimberley Wegner Lead Coordinator","Kimberley.wegner@hsc.utah.edu",{"name":156,"role":60,"phone":32,"phoneExt":32,"email":32},"Dr. Paul Bernstein",{"facility":158,"status":42,"city":159,"state":160,"zip":161,"country":162,"countryCode":163,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"Moorfields Eye Hospital NHS Foundation Trust","London","England","EC1V 2PD","United Kingdom","UK",{"type":49,"coordinates":165},[166,167],-0.12574,51.50853,{"lat":167,"lon":166},[170,173],{"name":171,"role":36,"phone":32,"phoneExt":32,"email":172},"Mithusa Pirabakaran","m.pirabakaran@nhs.net",{"name":174,"role":60,"phone":32,"phoneExt":32,"email":32},"Prof. Michel Michaelides",{"facility":176,"status":42,"city":159,"state":160,"zip":177,"country":162,"countryCode":163,"cosmosGeoPoint":178,"geoPoint":180,"contacts":181},"The Retina Clinic","W1G 9AY",{"type":49,"coordinates":179},[166,167],{"lat":167,"lon":166},[182,184],{"name":32,"role":36,"phone":32,"phoneExt":32,"email":183},"ctenquiries@theretinacliniclondon.com",{"name":185,"role":60,"phone":32,"phoneExt":32,"email":32},"Prof. Paulo-Eduardo Stanga",{"type":187,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[189],{"name":190,"class":191},"AAVantgarde Bio UK Ltd","UNKNOWN","100605363","phase-1-a-study-of-aavb-039-in-participants-with-stargardt-disease-stgd1-100605363",false,"NCT07161544","A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)","An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants With Stargardt Disease (STGD1) (CELESTE)","CELESTE","Inclusion Criteria:\n\n* Molecular diagnosis of Stargardt disease due to ABCA4 mutation\n* Willingness to adhere to protocol per informed consent\n\nExclusion Criteria:\n\n* Unwillingness to meet the requirements of the study\n* Participation in a clinical study with another Investigation Medicinal Product\n* Previous participation in another gene or cell therapy trial\n* Any condition that would preclude subretinal surgery\n* Complicating ocular and\u002For systemic diseases","ALL","8 Years","55 Years",{"count":204,"type":205},75,"ESTIMATED","INTERVENTIONAL",[208,209],"PHASE1","PHASE2","The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.",[212],"Stargardt Disease",[212,214,215,216],"Biallelic Mutation","Gene Mutation","ABCA4","2026-07-29",{"date":219,"type":220},"2026-07-30","ACTUAL",{"date":222,"type":220},"2025-09-29",{"date":224,"type":205},"2032-07",{"name":5,"class":6},9]